Replimune Group (NASDAQ:REPL) Issues Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Replimune Group (NASDAQ:REPL) announced its earnings results on Wednesday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09), Zacks reports.

Replimune Group Stock Performance

NASDAQ REPL traded up $0.53 on Wednesday, hitting $13.38. 327,286 shares of the company’s stock traded hands, compared to its average volume of 764,142. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00. The firm’s 50-day moving average price is $12.49 and its two-hundred day moving average price is $11.64. The firm has a market capitalization of $915.46 million, a PE ratio of -4.39 and a beta of 1.30.

Wall Street Analysts Forecast Growth

REPL has been the subject of a number of recent analyst reports. BMO Capital Markets upped their price target on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Jefferies Financial Group raised their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Finally, HC Wainwright lifted their price objective on shares of Replimune Group from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, January 22nd. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $19.14.

Insider Activity at Replimune Group

In related news, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares in the company, valued at $1,184,560.30. The trade was a 6.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.